IPO Year:
Exchange: NASDAQ
Website: aadibio.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/27/2024 | $5.00 → $1.75 | Overweight → Neutral | Piper Sandler |
| 8/21/2024 | $11.00 → $1.50 | Buy → Hold | Jefferies |
| 8/21/2024 | Buy → Hold | TD Cowen | |
| 12/15/2023 | Buy → Neutral | H.C. Wainwright | |
| 1/11/2022 | $45.00 | Buy | Jefferies |
| 11/24/2021 | $47.00 → $49.00 | Buy | HC Wainwright & Co. |
| 10/1/2021 | Outperform | Cowen & Co. | |
| 9/14/2021 | $51.00 | Buy | Ladenburg Thalmann |
| 9/8/2021 | $45.00 | Overweight | Piper Sandler |
| 8/30/2021 | $22.00 → $47.00 | Buy | HC Wainwright & Co. |
4 - Aadi Bioscience, Inc. (0001422142) (Issuer)
4 - Aadi Bioscience, Inc. (0001422142) (Issuer)
4 - Aadi Bioscience, Inc. (0001422142) (Issuer)
4 - Aadi Bioscience, Inc. (0001422142) (Issuer)
4 - Aadi Bioscience, Inc. (0001422142) (Issuer)
4 - Aadi Bioscience, Inc. (0001422142) (Issuer)
4 - Aadi Bioscience, Inc. (0001422142) (Issuer)
4 - Aadi Bioscience, Inc. (0001422142) (Issuer)
3 - Aadi Bioscience, Inc. (0001422142) (Issuer)
4 - Aadi Bioscience, Inc. (0001422142) (Issuer)
MORRISTOWN, N.J., March 14, 2025 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ:AADI) ("Aadi") today announced that it will host a webcast to discuss fourth quarter and full-year 2024 financial results and provide recent corporate updates on Wednesday, March 19, 2025. These results will be available under the "Investors & News" page of the Aadi Bioscience website at aadibio.com. About Aadi Bioscience Aadi is a precision oncology company with a vision to make bold choices in applying technology to efficiently deliver improved precision oncology therapies for people living with difficult-to-treat cancers. Contact:[email protected] View original content to download multimedia:https://w
MORRISTOWN, N.J., March 4, 2025 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ:AADI) ("Aadi"), an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver advances in cancer treatment, today announced the closing of its previously announced private placement. The private placement was led by Ally Bridge Group, with participation from new investors OrbiMed, Invus, Kalehua Capital and other accredited investors, Tae Han, co-founder of ProfoundBio, as well as existing investors, including Avoro Capital, KVP Capital and Acuta Capital Partners, for total gross proceeds of approximately $100 million. Aadi sold and issued an aggregate of 21,592
MORRISTOWN, N.J., March 3, 2025 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ:AADI), an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver advances in cancer treatment, today announced that the Company's stockholders have approved all proposals voted on at the Company's Special Meeting of Stockholders ("Special Meeting") held on February 28, 2025. Approved proposals include: Divestiture Proposal. The approval of the sale by Aadi to KAKEN INVESTMENTS INC. ("Kaken") of 100% of the outstanding shares of capital stock of Aadi Subsidiary, Inc. ("Aadi Sub") and thereby all or substantially all of Aadi's assets related to its FYARRO® (si
MORRISTOWN, N.J., Feb. 24, 2025 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ:AADI) announced today its presentation at the TD Cowen 45th Annual Healthcare Conference, taking place March 3-5, 2025, in Boston, MA. Dave Lennon, PhD, CEO, will present a company overview on Monday, March 3, 2025, from 9:50 – 10:20 AM ET. The presentation will be webcast live on the IR pages of the Aadi Bioscience website and will be available for replay for approximately 30 days following the investor event. About Aadi Bioscience Aadi is a precision oncology company with a vision to make bold choices in applying technology to efficiently deliver improved precision oncology therapies for people living with diffi
Seasoned Oncology Leader Brings Extensive ADC Expertise to Support Company's New Pipeline MORRISTOWN, N.J., Feb. 18, 2025 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ:AADI) today announced the appointment of David Dornan, PhD as the Company's Chief Scientific Officer (CSO). Dr. Dornan contributes more than two decades of experience in oncology drug discovery and development, with deep expertise in antibody-drug conjugates (ADCs) and other targeted cancer therapies. "David's extensive experience in ADC development and track record of translating novel oncology discoveries into clinical programs make him an ideal leader as we seek to rapidly advance our newly in-licensed ADC portfolio," said
Proxy Statement Includes Proposals on Previously Announced Sale of FYARRO and Associated Infrastructure to Kaken for $100M, and $100M PIPE Financing to Support In-Licensing of ADC Portfolio Aadi's Board Recommends Stockholders Vote "FOR" All Proposals to Support the Company's Business Transformation Company Expects to Close Transactions in the First Quarter of 2025, Subject to Stockholder Approval and Other Closing Conditions MORRISTOWN, N.J., Feb. 5, 2025 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ:AADI) ("Aadi" or the "Company") announced it filed its definitive proxy statement with the U.S. Securities and Exchange Commission (the "SEC") on January 31, 2025, and today mailed its definiti
Aadi Enters into Exclusive License for Three-Asset ADC Portfolio Developed through a Collaboration between WuXi Biologics and HANGZHOU DAC Aadi Enters Agreement to Sell FYARRO® and Associated Infrastructure to KAKEN Pharmaceutical for $100M; Announces PIPE Financing of $100M Cumulative Capital Expected to Fund Operations into Late 2028, Including Anticipated Clinical Data for the ADC Portfolio Co-Founder and Former CEO of ProfoundBio, Baiteng Zhao, Appointed to Aadi Board of Directors Aadi to Hold Webcast and Conference Call on December 20 at 8:00 AM EST LOS ANGELES, Dec. 19, 2024 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ:AADI) today announced it has entered into an exclusive license
LOS ANGELES, Oct. 30, 2024 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ:AADI) today announced that it will report third quarter 2024 financial results and provide recent corporate updates on Wednesday, November 6, 2024. These results will be available under the "Investors & News" page of the Aadi Bioscience website at aadibio.com. About Aadi Bioscience Aadi is a precision oncology company focused on the commercialization of FYARRO® for the treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa). More information on the Company is available on the Aadi website at www.aadibio.com and connect with us on Twitter and L
PRECISION1 tumor-agnostic trial unlikely to meet regulatory threshold to support an accelerated approval and will be halted Aadi will focus on FYARRO® commercial business for its approved indication, PEComa, and conduct a comprehensive strategic review to maximize shareholder value To further preserve cash position, Aadi will adjust ongoing Phase 2 trials and reduce R&D headcount by 80%, thereby extending cash runway into at least 2H 2026 LOS ANGELES, Aug. 20, 2024 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ:AADI) today announced it will halt the registration-intended PRECISION1 trial of nab-sirolimus in patients with solid tumors harboring TSC1 or TSC2 inactivating alterations. An analy
FYARRO® sales of $6.2 million for Q2 2024, a 15% quarter over quarter sales growth Interim analysis of two-thirds of fully enrolled PRECISION1 trial planned for Q3 2024 Conference call to be held today at 8:30 am EDT LOS ANGELES, Aug. 7, 2024 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ:AADI), a commercial-stage, precision oncology company focused on developing and commercializing therapies for cancers with alterations in the mTOR pathway, today announced financial results for the second quarter ended June 30, 2024, and highlighted recent corporate progress. "The second quarter saw quarter over quarter sales growth for FYARRO, as anticipated, and an increase in demand across both new and ex
Piper Sandler downgraded Aadi Bioscience from Overweight to Neutral and set a new price target of $1.75 from $5.00 previously
Jefferies downgraded Aadi Bioscience from Buy to Hold and set a new price target of $1.50 from $11.00 previously
TD Cowen downgraded Aadi Bioscience from Buy to Hold
H.C. Wainwright downgraded Aadi Bioscience from Buy to Neutral
Jefferies initiated coverage of Aadi Bioscience with a rating of Buy and set a new price target of $45.00
HC Wainwright & Co. reiterated coverage of Aadi Bioscience with a rating of Buy and set a new price target of $49.00 from $47.00 previously
Cowen & Co. initiated coverage of Aadi Bioscience with a rating of Outperform
Ladenburg Thalmann initiated coverage of Aadi Bioscience with a rating of Buy and set a new price target of $51.00
Piper Sandler initiated coverage of Aadi Bioscience with a rating of Overweight and set a new price target of $45.00
HC Wainwright & Co. reiterated coverage of Aadi Biosciences, Inc. - Common Stock with a rating of Buy and set a new price target of $47.00 from $22.00 previously
S-8 - Whitehawk Therapeutics, Inc. (0001422142) (Filer)
8-K - Whitehawk Therapeutics, Inc. (0001422142) (Filer)
8-K - Aadi Bioscience, Inc. (0001422142) (Filer)
D - Aadi Bioscience, Inc. (0001422142) (Filer)
SCHEDULE 13G - Aadi Bioscience, Inc. (0001422142) (Subject)
SCHEDULE 13D/A - Aadi Bioscience, Inc. (0001422142) (Subject)
8-K - Aadi Bioscience, Inc. (0001422142) (Filer)
SCHEDULE 13D/A - Aadi Bioscience, Inc. (0001422142) (Subject)
DEFA14A - Aadi Bioscience, Inc. (0001422142) (Filer)
DEFA14A - Aadi Bioscience, Inc. (0001422142) (Filer)
Dr. Lennon brings over 20 years of pharmaceutical experience, including deep expertise in the development and commercialization of mTOR inhibitors Leadership transition expected to accelerate growth and leverage ground-breaking nanoparticle technology in FYARRO® to build a leading precision oncology company On track for interim analysis on 40 patients in tumor agnostic PRECISION1 trial in patients with TSC1/TSC2 alterations and trial initiations in endometrial and neuroendocrine cancers before the end of 2023 LOS ANGELES, Oct. 2, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ:AADI), a biopharmaceutical company focused on developing and commercializing precision therapies with mTOR pathwa
LOS ANGELES, April 26, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ:AADI), a commercial-stage biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced the acceptance of abstracts for poster presentation at the upcoming 2023 ASCO Annual Meeting taking place June 2-6, 2023, in Chicago, IL. The presentations will consist of a company-sponsored Trials-in-Progress (TIP) update from the PRECISION 1 Phase 2 study and combination data of nab-sirolimus and pazopanib (PAZO) from an ongoing Investigator Initiated Trial. The details of the poster presentations are below: Title
LOS ANGELES, April 14, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ:AADI), a commercial-stage biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced the presentation of three posters at the 2023 American Association for Cancer Research Annual Meeting (AACR), taking place April 14-19, 2023, in Orlando, FL. The presentations at AACR 2023 include: a trials-in-progress (TIP) poster for the ongoing PRECISION 1 trial, a registrational directed tumor agnostic study for patients with solid tumors driven by TSC1 or TSC2 alterations; results on the anti-tumor activity of nab-s
LOS ANGELES, April 6, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ:AADI), a commercial-stage biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced that it will present three posters at the American Association for Cancer Research Annual Meeting (AACR) 2023, taking place April 14-19, 2023, in Orlando, FL. The details of the poster presentations are below: Title: "Phase 2, multicenter, open-label basket trial of nab-sirolimus for patients with inactivating alterations in TSC1 or TSC2 (PRECISION I)"Date and Time: Monday, April 17, 2023, 9:00 AM - 12:30 PMSession Title
LOS ANGELES, March 27, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ:AADI), a commercial-stage biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced the appointment of Mohammad Hirmand, M.D. to its Board of Directors. Dr. Hirmand has more than 20 years of biotechnology clinical development experience, and recently served as executive vice president and chief medical officer for Turning Point Therapeutics, which was acquired by Bristol Myers Squibb (BMS) for $4.1 billion in August 2022. "We welcome Mohammad to our Board at an exciting time for Aadi, as we advance the
LOS ANGELES, March 26, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ:AADI), a commercial-stage biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced that it presented data from its PRECISION 1 and AMPECT trials in two posters at the Society of Gynecological Oncology (SGO) Annual Meeting 2023, taking place March 25-28, 2023, in Tampa, FL. "We are pleased to present additional data with nab-sirolimus from our AMPECT trial and highlight our PRECISION 1 trial at SGO 2023, which is the premier medical meeting focused on advancing research for gynecologic cancer," said Lor
LOS ANGELES, March 3, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ:AADI), a commercial-stage biopharmaceutical company focused on precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced that Brendan Delaney has resigned for personal reasons from his position as Chief Executive Officer, President, and member of the Board of Directors of the Company. Scott Giacobello, currently the Company's Chief Financial Officer, has been appointed to serve as Interim Chief Executive Officer and President in addition to his current responsibilities. In addition, Neil Desai, Ph.D., the Founder of Aadi Bioscience and its President and CEO prior to Mr.
LOS ANGELES, Nov. 8, 2022 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ:AADI), a commercial-stage biopharmaceutical company focused on precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced the appointment of Neil Desai, Founder, President and CEO to Executive Chairman and Brendan Delaney, Chief Operating Officer, to President and CEO, effective as of January 1, 2023. "I have had the opportunity to work with Brendan since he joined Aadi as Chief Operating Officer in September 2021. Since that time his expertise and leadership have been instrumental in building the organization in preparation for the growth that lies ahead," said Neil Desa
LOS ANGELES, May 31, 2022 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (NASDAQ:AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes, today announced the appointment of Marcy Graham to the new position of Senior Vice President, Investor Relations (IR) and Corporate Communications. "We are delighted to welcome Marcy to the team, as she brings extensive experience to the senior role of investor relations and corporate communications and a strong history of relationship building with investors and other key external audiences," said Neil Desai, PhD, Founder, President and Chie
LOS ANGELES, Nov. 01, 2021 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. ("Aadi") (NASDAQ:AADI), a clinical-stage biopharmaceutical company focusing on precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced the appointment of Scott Giacobello, CPA, to the role of Chief Financial Officer (CFO) and Treasurer, effective November 28, 2021. Most recently, Mr. Giacobello was the Chief Financial Officer of GW Pharmaceuticals plc until its $7.2 billion acquisition by Jazz Pharmaceuticals. "We are delighted to have an outstanding executive like Scott join Aadi," stated Neil Desai, Ph.D., Founder, President and Chief Executive Officer of Aadi. "His
SC 13D/A - Aadi Bioscience, Inc. (0001422142) (Subject)
SC 13G - Aadi Bioscience, Inc. (0001422142) (Subject)
SC 13G - Aadi Bioscience, Inc. (0001422142) (Subject)
SC 13G/A - Aadi Bioscience, Inc. (0001422142) (Subject)
SC 13D/A - Aadi Bioscience, Inc. (0001422142) (Subject)
SC 13G - Aadi Bioscience, Inc. (0001422142) (Subject)
SC 13D/A - Aadi Bioscience, Inc. (0001422142) (Subject)
SC 13G - Aadi Bioscience, Inc. (0001422142) (Subject)
SC 13G/A - Aadi Bioscience, Inc. (0001422142) (Subject)
SC 13G/A - Aadi Bioscience, Inc. (0001422142) (Subject)
MORRISTOWN, N.J., March 14, 2025 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ:AADI) ("Aadi") today announced that it will host a webcast to discuss fourth quarter and full-year 2024 financial results and provide recent corporate updates on Wednesday, March 19, 2025. These results will be available under the "Investors & News" page of the Aadi Bioscience website at aadibio.com. About Aadi Bioscience Aadi is a precision oncology company with a vision to make bold choices in applying technology to efficiently deliver improved precision oncology therapies for people living with difficult-to-treat cancers. Contact:[email protected] View original content to download multimedia:https://w
LOS ANGELES, Oct. 30, 2024 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ:AADI) today announced that it will report third quarter 2024 financial results and provide recent corporate updates on Wednesday, November 6, 2024. These results will be available under the "Investors & News" page of the Aadi Bioscience website at aadibio.com. About Aadi Bioscience Aadi is a precision oncology company focused on the commercialization of FYARRO® for the treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa). More information on the Company is available on the Aadi website at www.aadibio.com and connect with us on Twitter and L
FYARRO® sales of $6.2 million for Q2 2024, a 15% quarter over quarter sales growth Interim analysis of two-thirds of fully enrolled PRECISION1 trial planned for Q3 2024 Conference call to be held today at 8:30 am EDT LOS ANGELES, Aug. 7, 2024 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ:AADI), a commercial-stage, precision oncology company focused on developing and commercializing therapies for cancers with alterations in the mTOR pathway, today announced financial results for the second quarter ended June 30, 2024, and highlighted recent corporate progress. "The second quarter saw quarter over quarter sales growth for FYARRO, as anticipated, and an increase in demand across both new and ex
Company to Host Conference Call and Webcast on August 7, 2024 LOS ANGELES, July 31, 2024 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ:AADI), a commercial-stage precision oncology company focused on developing and commercializing therapies for cancers with alterations in the mTOR pathway, today announced that it will host a conference call and live webcast on Wednesday, August 7, 2024, at 8:30 am EDT (5:30 am PDT) to report second quarter 2024 financial results and provide recent corporate updates. Conference Call Information Participants may access a live webcast of the call on the "Investors & News" page of the Aadi Bioscience website at aadibio.com. To participate via telephone, please re
Fully enrolled registration-intended PRECISION1 trial; two-thirds interim analysis planned for Q3 2024 FYARRO® sales of $5.4 million for Q1 2024, reflects distributor ordering patterns and fewer commercial patient initiations at the start of the year Conference call to be held today at 8:30 am EDT LOS ANGELES, May 8, 2024 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ:AADI), a commercial-stage, precision oncology company focused on developing and commercializing therapies for cancers with alterations in the mTOR pathway, today announced financial results for the first quarter ended March 31, 2024, and highlighted recent corporate progress. "I'm pleased to announce that PRECISION1 is now full
Company to Host Conference Call and Webcast on May 8, 2024 LOS ANGELES, May 1, 2024 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ:AADI), a commercial-stage precision oncology company focused on developing and commercializing therapies for cancers with alterations in the mTOR pathway, today announced that it will host a conference call and live webcast on Wednesday, May 8, 2024 at 8:30 am EDT (5:30 am PDT) to report first quarter 2024 financial results and provide recent corporate updates. Conference Call Information Participants may access a live webcast of the call on the "Investors & News" page of the Aadi Bioscience website at aadibio.com. To participate via telephone, please register in
FYARRO® sales of $6.3 million for Q4 2023 and $24.4 million for FY 2023 representing year-over-year growth of 21% and 60%, respectively Registration-directed PRECISION1 trial of nab-sirolimus in solid tumors with TSC1 or TSC2 inactivating alterations on track to complete enrollment by May; two-thirds interim analysis planned for Q3 2024 Phase 2 trials in Endometrial Cancer and Neuroendocrine Tumors (NETs) actively enrolling patients Conference call to be held today at 8:30 am EDT LOS ANGELES, March 13, 2024 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ:AADI), a commercial-stage, precision oncology company focused on developing and commercializing therapies for cancers with alterations in the
Company to Host Conference Call and Webcast on March 13, 2024 LOS ANGELES, March 6, 2024 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ:AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for patients with mTOR pathway alterations, today announced that it will host a conference call and live webcast on Wednesday, March 13, 2024 at 8:30 am ET (5:30 am PT) to report fourth quarter and full-year 2023 financial results and provide recent corporate updates. Conference Call Information Participants may access a live webcast of the call on the "Investors & News" page of the Aadi Bioscience website at aadibio.com. To participate via telephone, please regi
Interim results from investigator-assessed responses in first 40 patients from TSC1 and TSC2 arms demonstrate sustained tumor reductions in heavily pre-treated population 80 patients now enrolled in PRECISION1 supporting two-thirds interim analysis expected in 3Q 2024 Study on track for completion by end 2024; final data readout expected in early 2025 Company to host conference call today at 5:00 pm EST LOS ANGELES, Dec. 14, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ:AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes, today reported results from a planned interim anal
Continued growth in total revenue on FYARRO® with sales of $6.2 million for 2Q 2023 On-track for interim analysis on 40 patients in PRECISION1 trial before the end of 2023 Expanding pipeline to include programs in Endometrial Cancer and Neuroendocrine Tumors (NETs) Conference call to be held today at 8:30 am EST LOS ANGELES, Aug. 9, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ:AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes, today provided a corporate update and announced financial results for the second quarter of 2023. "We are seeing continued growth in FYARRO sale